share_log

22nd Century Eliminates an Additional $2.3 Million of Debt

22nd Century Eliminates an Additional $2.3 Million of Debt

22nd Century 免除了额外的 230 万美元债务
newsfile ·  05/13 08:00

Continues to Improve Balance Sheet and Move Toward Cash Positive Operations

继续改善资产负债表并转向现金正运营

Mocksville, North Carolina--(Newsfile Corp. - May 13, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction, today announced that it has entered into a binding letter of agreement to eliminate an additional $2.3 million in outstanding debt with JGB Capital.

北卡罗来纳州莫克斯维尔--(Newsfile Corp.,2024年5月13日)——专注于减少尼古丁危害的烟草制品公司22世纪集团公司(纳斯达克股票代码:XXII)今天宣布,它已签订一份具有约束力的协议书,取消与JGB Capital的额外230万美元未偿债务。

Under the terms of the agreement, the Company and JGB Capital will exchange an aggregate of $2.3M in principal, fees and expenses owed to JGB Capital for consideration of approximately 1.375 million shares of the Company's common stock and pre-funded warrants. Additionally, the Company will defer monthly amortization payments for an additional two months, resulting in no required further principal repayment until August 2024.

根据协议条款,公司和JGB Capital将把欠JGB Capital的总额230万美元的本金、费用和支出交换为公司约137.5万股普通股和预筹认股权证的对价。此外,公司将把每月摊还款再推迟两个月,因此无需在2024年8月之前进一步偿还本金。

Said Larry Firestone, Chairman and CEO: "This agreement with JGB is another significant step in restoring strength to our balance sheet as we work toward becoming debt free. This transaction also preserves our cash resources for commercial use as we work to become cash flow positive by the first quarter of 2025. We have made substantial progress on our commercial programs, including refining our revenue mix, implementing a lean operating cost profile and positioning the Company to win new contracts, including the new CMO and distribution agreements announced recently, which are already advancing our sales in the second quarter."

董事长兼首席执行官拉里·费尔斯通说:“在我们努力实现无债务的过程中,与日本国债的这项协议是恢复资产负债表实力的又一重要步骤。该交易还保留了我们的现金资源用于商业用途,因为我们正在努力到2025年第一季度实现正现金流。我们在商业计划方面取得了实质性进展,包括完善收入组合、实施精益运营成本配置以及为公司赢得新合同做好准备,包括最近宣布的新首席营销官和分销协议,这些协议已经推动了我们在第二季度的销售。”

"We thank JGB for being a constructive debtholder in helping us to negotiate this resolution and is a significant new equity holder in 22nd Century Group," added Firestone.

Firestone补充说:“我们感谢日本国银作为建设性的债务持有人,帮助我们就该决议进行了谈判,并且是22世纪集团的重要新股东。”

The details of the Company's transactions can be found in an 8-K filed with the Securities and Exchange Commission on May 10, 2024.

公司交易的详细信息可以在2024年5月10日向美国证券交易委员会提交的8-K中找到。

The shares of common stock, the pre-funded warrants, the newly issued warrants and shares issuable upon conversion are being issued in a private placement and were exempt from registration under the Securities Act of 1933, as amended, in reliance on Section 4(a)(2) thereof as a transaction not involving a public offering and/or Rule 506 of Regulation D promulgated thereunder.

普通股、预先注资的认股权证、新发行的认股权证和转换后可发行的股票均以私募方式发行,根据经修订的1933年《证券法》第4(a)(2)条作为不涉及公开发行的交易和/或据此颁布的D条例第506条的规定,免于注册。

This press release shall not constitute an offer to sell or the solicitation of any offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

本新闻稿不构成出售或征求任何购买此处讨论的证券的要约,也不得在根据任何此类州的证券法进行注册或资格认证之前,在任何州的证券要约、招标或出售是非法的。

About 22nd Century Group, Inc.
22nd Century Group, Inc. (NASDAQ: XXII) is an agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA's Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021. The Company is a subsequent participating manufacturer under the Master Settlement Agreement ("MSA") and vertically integrated for the production of its both own products and contract manufacturing operations ("CMO"), which consist primarily of branded filtered cigars and conventional cigarettes.

关于 22 世纪集团有限公司
22nd Century Group, Inc.(纳斯达克股票代码:XXII)是一家农业生物技术公司,专注于通过植物科学减少烟草危害、减少尼古丁烟草以及改善健康和保健。该公司拥有数十项专利,允许其控制烟草厂中的尼古丁生物合成,开发了专有的降低尼古丁含量(RNC)烟草植物和香烟,这些植物和香烟已成为美国食品药品管理局解决吸烟引起的大量死亡和疾病的综合计划的基石。2021年12月,该公司获得了美国食品药品管理局第一份也是唯一一份可燃香烟草产品(MRTP)授权。根据主和解协议(“MSA”),该公司随后成为参与的制造商,并进行垂直整合,生产自有产品和合同制造业务(“CMO”),主要包括品牌过滤雪茄和传统香烟。

Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube.
Learn more about VLN at tryvln.com.

在 xxiicentury.com、Twitter、LinkedIn 和 YouTube 上了解更多信息。
了解有关 VLN 的更多信息 在 tryvln.com。

Cautionary Note Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-Looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Forward-Looking statements include, but are not limited to, statements regarding (i) our strategic alternatives and cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, (iii) our financial and operating performance and (iv) our expectations for our business interruption insurance claim. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 28, 2024. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

关于前瞻性陈述的警示说明
除历史信息外,本新闻稿中包含的所有陈述、预期和假设均为前瞻性陈述,包括但不限于我们的全年业务展望。前瞻性陈述通常包含 “预测”、“相信”、“考虑”、“继续”、“可能”、“估计”、“预期”、“探索”、“预见”、“目标”、“指导”、“打算”、“可能”、“计划”、“潜在”、“预测”、“初步”、“可能”、“项目”、“有希望”、“寻求” 等术语、” “应该”、“将”、“将” 和类似的表达。前瞻性陈述包括但不限于有关以下内容的陈述:(i)我们的战略选择和成本削减计划,(ii)我们对监管执法的预期,包括我们获得新法规豁免的能力,(iii)我们的财务和经营业绩以及(iv)我们对业务中断保险索赔的预期。实际结果可能与前瞻性陈述中的明示或隐含结果存在重大差异。公司于2024年3月28日提交的10-K表年度报告中的 “风险因素” 中列出了可能导致实际业绩出现重大差异的重要因素。本新闻稿中提供的所有信息均为截至本新闻稿发布之日,除非法律要求,否则公司不承担任何义务也不打算更新这些前瞻性陈述。

Investor Relations & Media Contact
Matt Kreps
Investor Relations
22nd Century Group
mkreps@xxiicentury.com
214-597-8200

投资者关系与媒体联系人
马特·克雷普斯
投资者关系
22 世纪集团
mkreps@xxiicentury.com
214-597-8200

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发